Back to Search
Start Over
A long survival patient of anaplastic thyroid carcinoma treated with lenvatinib.
- Source :
-
Auris Nasus Larynx . Jun2022, Vol. 49 Issue 3, p515-519. 5p. - Publication Year :
- 2022
-
Abstract
- Anaplastic thyroid carcinoma (ATC) accounts for 1-2% of all malignant thyroid tumors. There are only a small number of patients with ATC and most of them die within 6 months after diagnosis, making it difficult to establish a standard treatment strategy. Although multimodal therapy, including radical surgery, radiotherapy, and chemotherapy, has been introduced, the survival rate remains poor. The use of molecular-targeted drugs for cancer therapy has become widely popular. Lenvatinib, a new molecular-targeted anticancer drug, is a multi-targeted receptor tyrosine kinase inhibitor (TKI). We report a rare case of a patient with ATC (T4N0M0) who responded extremely well to the administration of lenvatinib after radical surgery. Although ATC is one of the most fatal neoplasms, lenvatinib is a promising drug. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 03858146
- Volume :
- 49
- Issue :
- 3
- Database :
- Academic Search Index
- Journal :
- Auris Nasus Larynx
- Publication Type :
- Academic Journal
- Accession number :
- 156320212
- Full Text :
- https://doi.org/10.1016/j.anl.2020.10.005